ATE421337T1 - Adenovirus-formulierungen zur gentherapie - Google Patents
Adenovirus-formulierungen zur gentherapieInfo
- Publication number
- ATE421337T1 ATE421337T1 AT99960405T AT99960405T ATE421337T1 AT E421337 T1 ATE421337 T1 AT E421337T1 AT 99960405 T AT99960405 T AT 99960405T AT 99960405 T AT99960405 T AT 99960405T AT E421337 T1 ATE421337 T1 AT E421337T1
- Authority
- AT
- Austria
- Prior art keywords
- infectivity
- adenovirus
- gene therapy
- formulations
- adenovirus formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000701161 unidentified adenovirus Species 0.000 title abstract 3
- 238000001415 gene therapy Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000004067 bulking agent Substances 0.000 abstract 1
- 239000002577 cryoprotective agent Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10860698P | 1998-11-16 | 1998-11-16 | |
| US13311699P | 1999-05-07 | 1999-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE421337T1 true ATE421337T1 (de) | 2009-02-15 |
Family
ID=26806075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99960405T ATE421337T1 (de) | 1998-11-16 | 1999-11-16 | Adenovirus-formulierungen zur gentherapie |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1133316B1 (de) |
| AT (1) | ATE421337T1 (de) |
| AU (1) | AU1729600A (de) |
| CA (1) | CA2350890C (de) |
| DE (1) | DE69940354D1 (de) |
| DK (1) | DK1133316T3 (de) |
| ES (1) | ES2323991T3 (de) |
| WO (1) | WO2000029024A1 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003523320A (ja) * | 1999-09-29 | 2003-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途 |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| GB2408750B (en) * | 2003-12-02 | 2008-12-10 | Arthur A Codd | Preservation of biological material |
| US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
| DK1757312T3 (da) | 2004-06-14 | 2011-04-11 | Ishihara Sangyo Kaisha | Frysetørret sammensætning af inaktiveret viruskappe med membranfusionsaktivitet |
| CA2602944C (en) | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| KR101357685B1 (ko) * | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| MX2009004862A (es) | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| CA2795050C (en) | 2010-03-31 | 2018-05-22 | Stabilitech Ltd. | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| ES2757591T3 (es) | 2010-03-31 | 2020-04-29 | Stabilitech Biopharma Ltd | Estabilización de partículas virales |
| WO2011121301A1 (en) | 2010-03-31 | 2011-10-06 | Stabilitech Ltd | Excipients for stabilising viral particles, polypeptides or biological material |
| FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
| WO2012028315A1 (en) * | 2010-09-02 | 2012-03-08 | Sanofi Pasteur Sa | A stabilizer for the preparation of a dry polio injectable vaccine composition |
| US8771709B2 (en) | 2010-09-20 | 2014-07-08 | Crucell Holland B.V. | Therapeutic vaccination against active Tuberculosis |
| BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
| EP2646051A4 (de) | 2010-12-02 | 2014-05-28 | Oncolytics Biotech Inc | Flüssige virale formulierungen |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| US20120219590A1 (en) * | 2011-02-24 | 2012-08-30 | Paxvax, Inc. | Formulations useful for spray drying vaccines |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| CN103316356B (zh) * | 2012-03-22 | 2016-08-17 | 北京三诺佳邑生物技术有限责任公司 | 一种重组慢病毒载体制剂 |
| JP5805908B2 (ja) | 2012-03-22 | 2015-11-10 | クルセル ホランド ベー ヴェー | Ｒｓｖに対するワクチン |
| CN102755325B (zh) * | 2012-07-04 | 2013-05-29 | 深圳信立泰药业股份有限公司 | 一种头孢西丁钠药物组合物、其粉针剂及其制备方法 |
| KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드 |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| JP6013654B2 (ja) * | 2013-09-19 | 2016-10-25 | クルセル ホランド ベー ヴェー | 改良されたアデノウイルス製剤 |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| EP4523756A3 (de) | 2015-02-13 | 2025-05-28 | Transgene | Immunotherapeutischer impfstoff und antikörperkombinationstherapie |
| WO2016154055A1 (en) * | 2015-03-20 | 2016-09-29 | Bluebird Bio, Inc. | Vector formulations |
| JP6735288B2 (ja) | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| CN105219645B (zh) * | 2015-11-06 | 2018-09-25 | 南京农业大学 | 一种微生物保护剂及其应用 |
| JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| IL262108B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| CN109311946A (zh) | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| RU2745500C2 (ru) | 2016-06-20 | 2021-03-25 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
| WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| BR112019009113A2 (pt) * | 2016-11-04 | 2019-07-16 | Baxalta Incorporated | formulações de vírus adenoassociado |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| WO2018210871A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
| CN108703952B (zh) * | 2018-08-16 | 2021-05-07 | 张志刚 | 一种猪瘟口服弱毒冻干疫苗用冻干保护剂及应用 |
| MX2021005607A (es) | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
| TW202332458A (zh) * | 2019-04-19 | 2023-08-16 | 美商銳進科斯生物股份有限公司 | 腺相關病毒載體調配物及方法 |
| PH12022550240A1 (en) * | 2019-08-29 | 2022-12-19 | Astellas Pharma Inc | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| CN116904617B (zh) * | 2022-05-13 | 2026-03-31 | 北京中科生仪科技有限公司 | 一种斑疹伤寒核酸检测引物探针组合物及一体化微流控芯片试剂盒 |
| KR102838310B1 (ko) * | 2022-12-22 | 2025-07-25 | 주식회사 락토메이슨 | 유산균 동결보호제 |
| CN117414432B (zh) * | 2023-10-24 | 2025-12-05 | 北京智飞绿竹生物制药有限公司 | 一种稳定腺病毒载体冻干制剂及其应用 |
| CN119799654B (zh) * | 2024-12-30 | 2026-04-07 | 浙江大学 | 一种使假病毒常温稳定储存的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0761955B2 (ja) * | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥ａ型肝炎ワクチン |
| AU673827B2 (en) * | 1992-03-24 | 1996-11-28 | United Cancer Research Institute | Vaccine containing live virus for therapy of viral diseases and malignancies |
| US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
| EP0728195A1 (de) * | 1993-10-12 | 1996-08-28 | Chiron Corporation | Verfahren zur konservierung von rekombinanten retroviren |
| EP0738319A4 (de) * | 1994-01-12 | 2000-03-29 | Genetic Therapy Inc | Reinigung von retroviralen Vektoren |
| US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
| WO1998022588A2 (en) * | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| IL137510A0 (en) * | 1998-02-17 | 2001-07-24 | Schering Corp | Compositions comprising viruses and methods for concentrating virus preparations |
-
1999
- 1999-11-16 DK DK99960405T patent/DK1133316T3/da active
- 1999-11-16 DE DE69940354T patent/DE69940354D1/de not_active Expired - Lifetime
- 1999-11-16 EP EP99960405A patent/EP1133316B1/de not_active Expired - Lifetime
- 1999-11-16 AT AT99960405T patent/ATE421337T1/de active
- 1999-11-16 ES ES99960405T patent/ES2323991T3/es not_active Expired - Lifetime
- 1999-11-16 AU AU17296/00A patent/AU1729600A/en not_active Abandoned
- 1999-11-16 EP EP08006162A patent/EP1977764A1/de not_active Withdrawn
- 1999-11-16 CA CA2350890A patent/CA2350890C/en not_active Expired - Lifetime
- 1999-11-16 WO PCT/US1999/027177 patent/WO2000029024A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK1133316T3 (da) | 2009-05-25 |
| EP1133316B1 (de) | 2009-01-21 |
| DE69940354D1 (de) | 2009-03-12 |
| WO2000029024A9 (en) | 2000-11-02 |
| ES2323991T3 (es) | 2009-07-28 |
| CA2350890A1 (en) | 2000-05-25 |
| AU1729600A (en) | 2000-06-05 |
| EP1977764A1 (de) | 2008-10-08 |
| CA2350890C (en) | 2014-07-08 |
| WO2000029024A1 (en) | 2000-05-25 |
| EP1133316A1 (de) | 2001-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69940354D1 (de) | Adenovirus-formulierungen zur gentherapie | |
| DK1117440T3 (da) | Farmaceutiske sammensætninger indeholdende paclitaxel | |
| DE69725825D1 (de) | 5-HT1F-Agonisten | |
| DK0812198T3 (da) | Stabilisering af prostaglandinpræparater | |
| ID26033A (id) | Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan | |
| DE69938255D1 (de) | Verfahren und zusammensetzung zur konservierung von adenoviren | |
| DE60237696D1 (de) | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a | |
| ATE270557T1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
| BR9815419A (pt) | genes desaturase e uso dos mesmos | |
| PT1233784E (pt) | Composições e métodos para a estabilização de moléculas biológicas após a liofilização | |
| FI962799A0 (fi) | Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö | |
| EE9800248A (et) | Külmkuivatatud, vesiikuleid sisaldav ultraheli kontrastaine, selle valmistamismeetod ning ladustamise ja transpordi meetod, ultraheli kontrastaine keskkond ja selle valmistamismeetod ning külmkuivatuse stabilisaatorite kasutamine | |
| IL208697A0 (en) | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol | |
| BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
| DE69934998D1 (de) | Antisense modulation der expression von integrin alpha 4 | |
| BR0007201A (pt) | Composições incluindo agentes de preservação demalto-oligossacarìdeos reduzidos, e métodospara preservar um material | |
| ES2180319T3 (es) | Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos. | |
| EA199700032A1 (ru) | Дезинфицирующий состав "велтолен" | |
| ES2156375T3 (es) | Composicion de champu acondicionador. | |
| BRPI0418115A (pt) | formulação lìquida estável de hormÈnio de crescimento | |
| ATE314084T1 (de) | Kahalalid f formulierung | |
| ATE264340T1 (de) | Stabilisierung von gefriergetrocknetem kuchen | |
| DE69903666D1 (de) | Hilfsstoffe zur verwendung in adeno-assoziiertes virus enthaltenden pharmazeutischen zubereitungen und damit hergestellte pharmazeutische zubereitungen | |
| ID25478A (id) | Agonis 5-ht1f | |
| WO2022109294A3 (en) | Rna stabilization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1133316 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |